A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor
Latest Information Update: 25 Jul 2024
At a glance
- Drugs SAGE-324 (Primary)
- Indications Essential tremor
- Focus Therapeutic Use
- Acronyms KINETIC 2
- Sponsors Sage Therapeutics
- 24 Jul 2024 Results published in the Sage Therapeutics Media Release
- 14 Jun 2024 Status changed from active, no longer recruiting to completed.
- 01 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 May 2024.